OBJECTIVE: We evaluated the activity and safety of the combination of topotecan, cisplatin and bevacizumab in patients with recurrent or persistent carcinoma of the cervix. METHODS: Eligible patients had persistent or recurrent cervical cancer not amenable to curative intent treatment. No prior chemotherapy for recurrence was allowed. Treatment consisted of cisplatin 50 mg/m(2) day 1, topotecan 0.75 mg/m(2) days 1, 2 and 3 and bevacizumab 15 mg/kgday 1 every 21 days until disease progression or limiting toxicity. The primary endpoint was progression free survival at 6 months. We explored PET/CT as a potential early indicator of response to therapy. RESULTS: Twenty-seven eligible patients received a median of 3 treatment cycles (range, 1-19). Median follow-up was 10 months (range, 1.7-33.4). The 6-month PFS was 59% (80% CI: 46-70%). In 26 evaluable patients, we observed 1 CR (4%; 80% CI: 0.4-14%) and 8 PR (31%; 80% CI: 19-45%) lasting a median of 4.4 months. Ten patients had SD (39%; 80% CI: 25-53%) with median duration of 2.2 months. Median PFS was 7.1 months (80% CI: 4.7-10.1) and median OS was 13.2 months (80% CI: 8.0-15.4). All patients were evaluated for toxicity. Grade 3-4 hematologic toxicity was common (thrombocytopenia 82% leukopenia 74%, anemia 63%, neutropenia 56%). Most patients (78%) required unanticipated hospital admissions for supportive care and/or management of toxicities. CONCLUSION: The addition of bevacizumab to topotecan and cisplatin results in an active but highly toxic regimen. Future efforts should focus on identification of predictive biomarkers of prolonged response and regimen modifications to minimize toxicity.
OBJECTIVE: We evaluated the activity and safety of the combination of topotecan, cisplatin and bevacizumab in patients with recurrent or persistent carcinoma of the cervix. METHODS: Eligible patients had persistent or recurrent cervical cancer not amenable to curative intent treatment. No prior chemotherapy for recurrence was allowed. Treatment consisted of cisplatin 50 mg/m(2) day 1, topotecan 0.75 mg/m(2) days 1, 2 and 3 and bevacizumab 15 mg/kgday 1 every 21 days until disease progression or limiting toxicity. The primary endpoint was progression free survival at 6 months. We explored PET/CT as a potential early indicator of response to therapy. RESULTS: Twenty-seven eligible patients received a median of 3 treatment cycles (range, 1-19). Median follow-up was 10 months (range, 1.7-33.4). The 6-month PFS was 59% (80% CI: 46-70%). In 26 evaluable patients, we observed 1 CR (4%; 80% CI: 0.4-14%) and 8 PR (31%; 80% CI: 19-45%) lasting a median of 4.4 months. Ten patients had SD (39%; 80% CI: 25-53%) with median duration of 2.2 months. Median PFS was 7.1 months (80% CI: 4.7-10.1) and median OS was 13.2 months (80% CI: 8.0-15.4). All patients were evaluated for toxicity. Grade 3-4 hematologic toxicity was common (thrombocytopenia 82% leukopenia 74%, anemia 63%, neutropenia 56%). Most patients (78%) required unanticipated hospital admissions for supportive care and/or management of toxicities. CONCLUSION: The addition of bevacizumab to topotecan and cisplatin results in an active but highly toxic regimen. Future efforts should focus on identification of predictive biomarkers of prolonged response and regimen modifications to minimize toxicity.
Authors: Lalitha K Shankar; John M Hoffman; Steve Bacharach; Michael M Graham; Joel Karp; Adriaan A Lammertsma; Steven Larson; David A Mankoff; Barry A Siegel; Annick Van den Abbeele; Jeffrey Yap; Daniel Sullivan Journal: J Nucl Med Date: 2006-06 Impact factor: 10.057
Authors: Jason D Wright; Dana Viviano; Matthew A Powell; Randall K Gibb; David G Mutch; Perry W Grigsby; Janet S Rader Journal: Gynecol Oncol Date: 2006-05-02 Impact factor: 5.482
Authors: Noan-Minh Chau; Paul Rogers; Wynne Aherne; Veronica Carroll; Ian Collins; Edward McDonald; Paul Workman; Margaret Ashcroft Journal: Cancer Res Date: 2005-06-01 Impact factor: 12.701
Authors: Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman Journal: CA Cancer J Clin Date: 2011-02-04 Impact factor: 508.702
Authors: Elizabeth A Kidd; Barry A Siegel; Farrokh Dehdashti; Janet S Rader; David G Mutch; Matthew A Powell; Perry W Grigsby Journal: J Clin Oncol Date: 2010-03-22 Impact factor: 44.544
Authors: Harry J Long; Brian N Bundy; Edward C Grendys; Jo Ann Benda; D Scott McMeekin; Joel Sorosky; David S Miller; Lynne A Eaton; James V Fiorica Journal: J Clin Oncol Date: 2005-05-23 Impact factor: 44.544
Authors: Bradley J Monk; Michael W Sill; Robert A Burger; Heidi J Gray; Thomas E Buekers; Lynda D Roman Journal: J Clin Oncol Date: 2009-01-12 Impact factor: 44.544
Authors: Bradley J Monk; Michael W Sill; D Scott McMeekin; David E Cohn; Lois M Ramondetta; Cecelia H Boardman; Jo Benda; David Cella Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544
Authors: A Godoy-Ortiz; Y Plata; J Alcaide; A Galeote; B Pajares; E Saez; E Alba; A Sánchez-Muñoz Journal: Clin Transl Oncol Date: 2017-12-08 Impact factor: 3.405
Authors: Lingegowda S Mangala; Hongyu Wang; Dahai Jiang; Sherry Y Wu; Anoma Somasunderam; David E Volk; Ganesh L R Lokesh; Xin Li; Sunila Pradeep; Xianbin Yang; Monika Haemmerle; Cristian Rodriguez-Aguayo; Archana S Nagaraja; Rajesha Rupaimoole; Emine Bayraktar; Recep Bayraktar; Li Li; Takemi Tanaka; Wei Hu; Cristina Ivan; Kshipra M Gharpure; Michael H McGuire; Varatharasa Thiviyanathan; Xinna Zhang; Sourindra N Maiti; Nataliya Bulayeva; Hyun-Jin Choi; Piotr L Dorniak; Laurence Jn Cooper; Kevin P Rosenblatt; Gabriel Lopez-Berestein; David G Gorenstein; Anil K Sood Journal: JCI Insight Date: 2016-10-20